HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sebelius Plans To Leave Plan B Decision To Science

This article was originally published in The Tan Sheet

Executive Summary

Doctors and scientists, not politicians, must evaluate the safety of the emergency contraceptive Plan B, says Kathleen Sebelius, the Department of Health and Human Services secretary nominee

You may also be interested in...



FDA Will Wait To Act On Plan B Petition Despite Contempt Complaint

FDA does not plan to look at allowing wider access to nonprescription emergency contraceptive Plan B until Teva Pharmaceuticals files an application, despite a complaint accusing the agency of ignoring a court order to reconsider age restrictions on the product.

Plan B Lightning May Strike Again: Complying Will Not End Political Storm

Perpetual political lightning rod - and emergency contraceptive - Plan B has another chance to draw strikes to FDA as the agency has chosen to comply with a court ruling ordering it to reconsider whether the drug should be available in a truly over-the counter setting

Plan B Lightning May Strike Again: Compliance May Not End Political Storm

Perpetual political lightning rod - and emergency contraceptive - Plan B will have more chances to draw strikes to FDA as the agency chooses to comply with a court ruling ordering it to reconsider whether the drug should be available in a truly over-the-counter setting

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS135590

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel